Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 483.5 DKK 2.49% Market Closed
Market Cap: 97.7B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Total Liabilities & Equity
kr38.6B
CAGR 3-Years
20%
CAGR 5-Years
34%
CAGR 10-Years
30%
Zealand Pharma A/S
CSE:ZEAL
Total Liabilities & Equity
kr9.6B
CAGR 3-Years
80%
CAGR 5-Years
41%
CAGR 10-Years
39%
Ascendis Pharma A/S
NASDAQ:ASND
Total Liabilities & Equity
€758.3m
CAGR 3-Years
-4%
CAGR 5-Years
0%
CAGR 10-Years
44%
B
Bavarian Nordic A/S
CSE:BAVA
Total Liabilities & Equity
kr14.3B
CAGR 3-Years
13%
CAGR 5-Years
40%
CAGR 10-Years
28%
F
Fluoguide AS
STO:FLUO
Total Liabilities & Equity
kr29.6m
CAGR 3-Years
21%
CAGR 5-Years
230%
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Total Liabilities & Equity
kr131.5m
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
12%
No Stocks Found

Genmab A/S
Glance View

Market Cap
94.2B DKK
Industry
Biotechnology

Genmab A/S is a cutting-edge biotechnology company based in Denmark, renowned for its pioneering approach to developing differentiated antibody therapies for the treatment of cancer. Founded in 1999, the company focuses on harnessing the power of the immune system to combat various malignancies. Its flagship product, Darzalex (daratumumab), has transformed treatment protocols for multiple myeloma, achieving robust sales and establishing Genmab as a formidable player in the oncology landscape. The company's innovative platform combines proprietary technologies and skilled teams to create next-generation therapies, underscoring its commitment to improving patients' lives through targeted and effective cancer treatment solutions. As Genmab continues to build on its success, it is also expanding its pipeline with a diverse array of promising assets in various stages of clinical development. Not only does this validate its research capabilities, but it also positions Genmab for substantial future growth. The company's strategic collaborations with major pharmaceutical partners, such as Johnson & Johnson, further amplify its reach and resource capabilities, fostering a collaborative approach to accelerate drug development. With a solid financial standing and a focus on sustained innovation, Genmab A/S presents an intriguing investment opportunity for those looking to tap into the evolving landscape of biotechnology and oncology therapeutics.

GMAB Intrinsic Value
2 507.16 DKK
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Genmab A/S's Total Liabilities & Equity?
Total Liabilities & Equity
38.6B DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Total Liabilities & Equity amounts to 38.6B DKK.

What is Genmab A/S's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
30%

Over the last year, the Total Liabilities & Equity growth was 21%. The average annual Total Liabilities & Equity growth rates for Genmab A/S have been 20% over the past three years , 34% over the past five years , and 30% over the past ten years .

Back to Top